<DOC>
	<DOCNO>NCT01158937</DOCNO>
	<brief_summary>Meropenem intravenous antibiotic commonly use treat acute exacerbation respiratory infection cystic fibrosis . The research study aim determine different method infuse drug 3 hour longer , instead traditional half-hour improve target attainment drug concentration bactericidal activity . A secondary aim ass pharmacokinetics meropenem different active infection compare non-infective stage . Twelve patient admit acute respiratory infection require meropenem enrolled study . Meropenem blood concentration collect 8 hour measure half-hour 3-hour infusion different day . A pharmacokinetic modelling Monte Carlo simulation program use data ass predict optimal method dosing . When patient return follow-up clinic visit , single dose meropenem administer blood concentration measure determine pharmacokinetics non-infective stage .</brief_summary>
	<brief_title>Pharmacokinetic Study Extended Infusion Meropenem Adult Cystic Fibrosis Patients</brief_title>
	<detailed_description>Meropenem play crucial role treatment pulmonary exacerbation cystic fibrosis patient , activity P. aeruginosa B. cepacia , two problematic pathogen encounter disease . These organism cause chronic endobronchitis frequent exacerbation lead significant morbidity premature mortality . Treatment option pulmonary exacerbation limit due high rate resistance currently available antibiotic lack development new effective antibiotic . Therefore optimization dose meropenem , use extend infusion strategy , one method allow u maximize efficacy drug . Meropenem beta-lactam type antibiotic time-dependent bactericidal activity hence suitable extend infusion dose . The key rationale extend infusion beta-lactam antibiotic allow optimization pharmacodynamic target attainment time minimal inhibitory concentration ( T &gt; MIC ) maximize bactericidal kill optimize clinical outcome . The use infusion strategy study non-cystic fibrosis patient treat primarily piperacillin-tazobactam meropenem P. aeruginosa infection . The application strategy cystic fibrosis patient well study , data treatment B. cepacia infection . Also pharmacokinetic characteristic meropenem adult cystic fibrosis patient pulmonary exacerbation previously study . It unclear whether pharmacokinetic profile meropenem patient without exacerbation accurately extrapolate patient exacerbation . The first phase study , therefore , describe pharmacokinetic profile meropenem distribution MICs P. aeruginosa B. cepacia population adult cystic fibrosis patient pulmonary exacerbation . The data use determine optimal extend infusion dose strategy specifically patient cystic fibrosis . The second phase study provide additional data pharmacokinetics meropenem patient without active infection . Significance study : This study provide new information regard pharmacokinetics meropenem population cystic fibrosis patient pulmonary exacerbation . This allow u apply Monte Carlo simulation data set great confidence directly reflect target population . Optimization meropenem dose base pharmacodynamic profile Monte Carlo simulation lay groundwork clinical efficacy study future . Based result previous study , optimization meropenem dose potential produce well patient outcome , reduce drug utilization cost reduce rate resistance . These examined future clinical study .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Thienamycins</mesh_term>
	<criteria>≥18 year old , currently experience new exacerbation active pulmonary infection evidence increased coughing , sputum production , wheeze , white blood count and/or fever , require meropenem treatment , recent sputum culture positive P. aeruginosa and/or B. cepacia prior visit , able provide write informed consent . hypersensitivity and/or intolerance meropenem , history seizure , current use valproic acid , significant psychiatric illness , contraindication insertion venous catheter , worsen clinical status require admission intensive care unit ( ICU ) , creatinine clearance ≤50 ml/min , significant cystic fibrosisrelated liver dysfunction characterize portal hypertension cirrhosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>meropenem</keyword>
	<keyword>cystic fibrosis</keyword>
	<keyword>extend infusion</keyword>
	<keyword>pharmacokinetic</keyword>
</DOC>